Companies › Lyvgen Biopharma Holdings
1 active drug program in 1 registered trial: 1 Phase 2; Oncology; next expected readout Oct 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| LVGN6051 4-1BB agonistic antibody | TNFRSF9 | Phase 2 | Head and Neck Squamous Cell Carcinoma | Oct 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06378177 | LVGN6051 | Phase 2 | Head and Neck Squamous Cell Carcinoma | Oncology | Oct 2027 |
Pieris Pharmaceuticals iOnctura Toray Industries SynerGene Therapeutics Imvax
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.